DE69621521D1 - Cyclodextrinderivate, ihre Herstellung und Verwendung zur Einbringung von hydrophoben Molekülen in strukturierten Tensidsystemen - Google Patents
Cyclodextrinderivate, ihre Herstellung und Verwendung zur Einbringung von hydrophoben Molekülen in strukturierten TensidsystemenInfo
- Publication number
- DE69621521D1 DE69621521D1 DE69621521T DE69621521T DE69621521D1 DE 69621521 D1 DE69621521 D1 DE 69621521D1 DE 69621521 T DE69621521 T DE 69621521T DE 69621521 T DE69621521 T DE 69621521T DE 69621521 D1 DE69621521 D1 DE 69621521D1
- Authority
- DE
- Germany
- Prior art keywords
- introduction
- production
- cyclodextrin derivatives
- surfactant systems
- hydrophobic molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9507841A FR2736056B1 (fr) | 1995-06-29 | 1995-06-29 | Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69621521D1 true DE69621521D1 (de) | 2002-07-11 |
DE69621521T2 DE69621521T2 (de) | 2003-01-02 |
Family
ID=9480518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69621521T Expired - Fee Related DE69621521T2 (de) | 1995-06-29 | 1996-06-27 | Cyclodextrinderivate, ihre Herstellung und Verwendung zur Einbringung von hydrophoben Molekülen in strukturierten Tensidsystemen |
Country Status (8)
Country | Link |
---|---|
US (1) | US5821349A (de) |
EP (1) | EP0751150B1 (de) |
JP (1) | JPH0912605A (de) |
AU (1) | AU699482B2 (de) |
DE (1) | DE69621521T2 (de) |
FR (1) | FR2736056B1 (de) |
HU (1) | HUP9601791A3 (de) |
ZA (1) | ZA965364B (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2792942B1 (fr) | 1999-04-29 | 2001-06-08 | Commissariat Energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
AU2001250892A1 (en) * | 2000-03-20 | 2001-10-03 | Teva Pharmaceutical Industries Ltd. | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n-(4-methoxyphenyl)-3-chloropropionamide |
JP2003531930A (ja) * | 2000-04-28 | 2003-10-28 | ユニバーシティ・カレッジ・ダブリン | 両親媒性大環状誘導体およびそれらの類似体 |
US6527887B1 (en) | 2002-01-18 | 2003-03-04 | Mach I, Inc. | Polymeric cyclodextrin nitrate esters |
FR2861396B1 (fr) | 2003-10-24 | 2005-12-16 | Commissariat Energie Atomique | Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations |
WO2006001844A2 (en) * | 2004-01-29 | 2006-01-05 | Pinnacle Pharmaceuticals | β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN |
KR20070101347A (ko) * | 2005-01-28 | 2007-10-16 | 핀나클 파마슈티컬스, 인코포레이티드 | 항균제로서의 β시클로덱스트린 유도체 |
JP5364923B2 (ja) * | 2009-01-28 | 2013-12-11 | 学校法人福岡大学 | 多機能性シクロデキストリン誘導体、その包接化合物およびそれらの製造方法。 |
WO2010113983A1 (ja) | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
HUE029577T2 (en) | 2009-03-30 | 2017-03-28 | Eisai R&D Man Co Ltd | Liposome preparation |
US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
-
1995
- 1995-06-29 FR FR9507841A patent/FR2736056B1/fr not_active Expired - Fee Related
-
1996
- 1996-06-07 US US08/659,824 patent/US5821349A/en not_active Expired - Fee Related
- 1996-06-24 AU AU56164/96A patent/AU699482B2/en not_active Ceased
- 1996-06-25 ZA ZA965364A patent/ZA965364B/xx unknown
- 1996-06-26 JP JP8166429A patent/JPH0912605A/ja active Pending
- 1996-06-27 DE DE69621521T patent/DE69621521T2/de not_active Expired - Fee Related
- 1996-06-27 EP EP96401426A patent/EP0751150B1/de not_active Expired - Lifetime
- 1996-06-28 HU HU9601791A patent/HUP9601791A3/hu unknown
Also Published As
Publication number | Publication date |
---|---|
JPH0912605A (ja) | 1997-01-14 |
US5821349A (en) | 1998-10-13 |
HUP9601791A3 (en) | 1997-08-28 |
FR2736056A1 (fr) | 1997-01-03 |
EP0751150A1 (de) | 1997-01-02 |
AU699482B2 (en) | 1998-12-03 |
DE69621521T2 (de) | 2003-01-02 |
AU5616496A (en) | 1997-01-09 |
HUP9601791A2 (en) | 1997-05-28 |
EP0751150B1 (de) | 2002-06-05 |
HU9601791D0 (en) | 1997-06-30 |
FR2736056B1 (fr) | 1997-08-08 |
ZA965364B (en) | 1997-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO991942D0 (no) | FremgangsmÕte for fremstilling av malonat metyliden nanopartikler, nanopartikler eventuelt inneholdende en eller flere biologisk aktive molekyler | |
ATE233241T1 (de) | Stabile reagenzien zur herstellung von radiopharmazeutika | |
DE69724142D1 (de) | Sulfonamid-derivate, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel | |
DE59404480D1 (de) | Fullerenderivate, verfahren zur herstellung und deren verwendung | |
DE69505296D1 (de) | Erythromycinderivate, ihre Verfahren zur Herstellung und ihre Verwendung als Arzneimittel | |
DE69506496D1 (de) | Verfahren zur Herstellung von modifizierten Harzen und ihre Verwendungen | |
ATE207707T1 (de) | Adsorbens für phosphat aus wässrigem medium, dessen herstellung und verwendung | |
EP0863762A4 (de) | Verfahren zur herstellung und verwendung von flüssigformulierungen mit plasmaproteinen | |
DE69306796D1 (de) | Herstellung von feststoffen im nano-bereich | |
DE69203958D1 (de) | Produktionssystem zur Herstellung von Kleidung und anderen Produkten. | |
DE69627659D1 (de) | Neue thrombin-inhibitoren, deren herstellung und verwendung | |
DE69903464D1 (de) | Haftverschlüsse, deren herstellung und sie aufweisenden produkten | |
EP1100496A4 (de) | Kleine moleküle die bcl-2 proteine hemmen | |
DE69623992D1 (de) | Derivate von dolestatin, deren herstellung und verwendung | |
DE69716224D1 (de) | Vorrichtungen zur Herstellung von Feinpartikeln | |
DE69712610D1 (de) | Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel | |
DE69711230D1 (de) | Biologisch aktive substanzen, verfahren zur herstellung und sie enthaltende zusammensetzungen | |
DE59303423D1 (de) | Wachsdispersionen, deren herstellung und verwendung | |
DE59711006D1 (de) | Emulgatormischungen und deren verwendung zur herstellung von pit-emulsionen | |
DE69621521D1 (de) | Cyclodextrinderivate, ihre Herstellung und Verwendung zur Einbringung von hydrophoben Molekülen in strukturierten Tensidsystemen | |
DE69625857D1 (de) | Siliconderivate, ihre Herstellung und Verwendung | |
ATE203293T1 (de) | Leimungsmittel vom 2-oxetanone-typ und ihre herstellung und verwendung | |
BR9607023A (pt) | Método para produção de aminoetilenolamina e/ou hidroxietil piperazina | |
ATE195937T1 (de) | Pyridazinone-derivate und verfahren zur deren herstellung | |
DE59606486D1 (de) | Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |